Lajos Pusztai, MD, DPhil

Articles

Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer

July 20th 2024

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

Dr Pusztai on the Launch of the DARE Study in ER+/HER2– High-Risk Breast Cancer

December 15th 2023

Lajos Pusztai, MD, DPhil, discusses the phase 2 DARE trial evaluating circulating tumor DNA-guided second-line adjuvant therapy for patients with high-risk, stage II-III, estrogen receptor-positive, HER2-negative breast cancer, highlighting the importance of researching ctDNA utility in this patient population.

Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer

April 29th 2020

Lajos Pusztai, MD, DPhil, discusses the rationale for the phase 2 I-SPY 2 trial examining the addition of durvalumab and olaparib to neoadjuvant paclitaxel in HER2-negative breast cancer.

Clinical Utility of Emerging Molecular Diagnostics in Breast Cancer

March 9th 2016

The past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.

Dr. Pusztai Discusses BCI in Patients With ER-Positive/HR-Positive Breast Cancer

August 18th 2015

Lajos Pusztai, MD, DPhil, professor of Medicine (Medical Oncology), chief, Breast Medical Oncology, co-director, Cancer Genetics Research Program, Yale Cancer Center, discusses the Breast Cancer Index in patients with ER-positive/HR-positive breast cancer.